Mackenzie Financial Corp lifted its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 61.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 8,308 shares of the company’s stock after buying an additional 3,162 shares during the quarter. Mackenzie Financial Corp’s holdings in Alkermes were worth $455,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its stake in shares of Alkermes by 7.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,804 shares of the company’s stock worth $336,000 after buying an additional 409 shares during the last quarter. CIBC Asset Management Inc lifted its stake in shares of Alkermes by 12.6% during the 4th quarter. CIBC Asset Management Inc now owns 7,287 shares of the company’s stock worth $399,000 after buying an additional 818 shares during the last quarter. Public Employees Retirement Association of Colorado lifted its stake in shares of Alkermes by 3.2% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 31,504 shares of the company’s stock worth $1,724,000 after buying an additional 970 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Alkermes by 4.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,855 shares of the company’s stock worth $1,908,000 after buying an additional 1,462 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Alkermes by 0.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 196,108 shares of the company’s stock worth $11,369,000 after buying an additional 1,577 shares during the last quarter.
Shares of Alkermes Plc (NASDAQ:ALKS) opened at $60.53 on Tuesday. Alkermes Plc has a 12 month low of $46.42 and a 12 month high of $71.22. The company has a quick ratio of 2.46, a current ratio of 2.78 and a debt-to-equity ratio of 0.23. The firm has a market cap of $9,007.99, a PE ratio of -58.77 and a beta of 1.87.
In other Alkermes news, CAO Iain Michael Brown sold 10,652 shares of the firm’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $54.81, for a total value of $583,836.12. Following the transaction, the chief accounting officer now directly owns 16,943 shares of the company’s stock, valued at approximately $928,645.83. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $54.99, for a total transaction of $54,990.00. Following the completion of the transaction, the director now directly owns 9,000 shares in the company, valued at $494,910. The disclosure for this sale can be found here. Insiders sold a total of 125,433 shares of company stock valued at $7,942,327 in the last quarter. Corporate insiders own 5.34% of the company’s stock.
A number of analysts have recently issued reports on the stock. Morgan Stanley restated an “equal weight” rating and set a $67.00 target price (up previously from $60.00) on shares of Alkermes in a research note on Friday, February 23rd. Jefferies Group cut shares of Alkermes from a “buy” rating to a “hold” rating and raised their target price for the stock from $63.19 to $66.00 in a research note on Thursday, February 22nd. Cantor Fitzgerald restated a “hold” rating and set a $50.00 target price on shares of Alkermes in a research note on Tuesday, February 20th. Credit Suisse Group raised their target price on shares of Alkermes from $66.00 to $70.00 and gave the stock an “outperform” rating in a research note on Friday, February 16th. Finally, Citigroup set a $62.00 target price on shares of Alkermes and gave the stock a “hold” rating in a research note on Thursday, February 15th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. Alkermes has an average rating of “Hold” and a consensus price target of $64.58.
ILLEGAL ACTIVITY NOTICE: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3259320/mackenzie-financial-corp-boosts-stake-in-alkermes-plc-alks.html.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.